Boehringer Ingelheim Invests in the Health of Albertans
Boehringer Ingelheim Canada is committed to improving the lives of Canadians and has made two major investments with the University Hospital Foundation to propel this goal forward. Boehringer Ingelheim is a family-owned research-driven pharmaceutical company. Through the power of these partnerships, we accelerate the delivery of the next medical breakthrough that will transform the lives of countless patients now, and in the future.
Current investments include:
Developing solutions for Albertans who struggle to breath
Thousands of Canadians suffer from Interstitial Lung Diseases (ILD), an estimated 18 to 32% of those patients will develop a Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) course of the disease which causes the lungs to become progressively scarred, thickened and stiff, which worsens lung function, quality of life, and can result in death or disability.
The partnership between Boehringer Ingelheim Canada and The University Hospital Foundation through the Alberta Boehringer Ingelheim Interstitial Lung Diseases Collaboration (ABILD) aims to optimize patient care from testing, assessing and providing care and support to improve the lives of those living with PF-ILD.
Alberta Boehringer Ingelheim Collaboration (ABIC)
In June 2019, a partnership with Boehringer Ingelheim (Canada) Ltd., the University Hospital Foundation and the Government of Alberta was established. The collaborative is a public-private philanthropic partnership created to focus on developing solutions to address treatment gaps in the area of Chronic Obstructive Pulmonary Disease (COPD) care and its associated comorbidities including diabetes, obesity and heart failure.
Primary objectives of the partnership are:
- Prevention of progression of patients with COPD
- Management of COPD related co-morbidities including diabetes and heart failure, and keeping patients in their communities
- Improve COPD for patients within Alberta’s vulnerable populations and design innovations to address these challenges
Alberta Boehringer Ingelheim Interstitial Lung Diseases Collaboration (ABILD)
On September 25, 2019, World Lung Day, the University Hospital Foundation and Boehringer Ingelheim Canada announced another investment into progressive fibrosing interstitial lung disease (PF-ILD).
Interstitial lung diseases encompass more than 200 disorders that can lead to irreversible scarring of lung tissue, negatively impacting lung function. ABILD aims to advance health innovation projects to gain a better understanding of care gaps in diagnosis, patient care, and access to treatment for Albertans living with PF-ILD.
Through strategic partnerships we accelerate health innovation projects
ABIC 2021 RESEARCH COMPETITION
ABIC, in partnership with Boehringer Ingelheim, the University Hospital Foundation, and Government of Alberta Ministry of Jobs, Economy and Innovation, is pleased to invite proposals from Alberta-based investigators or teams of investigators for funding to address the management of COPD related co-morbidities (specifically diabetes and heart failure) and keeping patients in their communities.
The 2021 ABIC Research Competition is now closed.
ABIC 2019 Research Competition Winners
Dr. Michael K. Stickland
Project Title: Breathe Easy Pulmonary Rehabilitation
Pulmonary rehabilitation is a multidisciplinary ambulatory intervention that includes assessment, exercise training, self-management education, and psychosocial support. The project will provide pulmonary rehabilitation program resources to patients/families and health care professionals in order to improve shortness of breath, exercise tolerance and quality of life in patients with COPD, with the potential of reducing the consequent increase in acute care demand for this population.
Dr. Heather Sharpe
Project Title: Identifying Early COPD Using Health Administrative Data
This innovative project will use machine learning to identify trends in healthcare that will eventually lead to earlier diagnosis of Chronic Obstructive Pulmonary Disease (COPD). Machine learning gives doctors critical insights from mountains of data and the partners are grateful for AltaML’s investment into this project .This has the potential to improve quality of life for patients living with COPD and delay the need for prolonged hospitalizations and frequent emergency department visits.